CRYOPORT INC (CYRX)
Health Care · Cell and gene therapy supply chain / temperature-controlled life sciences logistics · NASDAQ
Cryoport is the leading provider of end-to-end temperature-controlled supply chain solutions specifically built for cell and gene therapies, from preclinical development through global commercialization.
What CRYOPORT INC does
Cryoport is a leading provider of integrated, temperature-controlled supply chain solutions for the life sciences, with specialization in cell and gene therapy (CGT). The company operates through three business units—Cryoport Systems (BioLogistics, BioServices, and cryopreservation), CryoGene (long-term biostorage), and MVE Biological Solutions (cryogenic equipment manufacturing)—delivering end-to-end Chain of Compliance solutions for clinical trials and commercialized therapies. As of December 2025, Cryoport supported 760 clinical trials and 20 commercially approved cell and gene therapies.
Themes: Cell and gene therapy supply chain, Temperature-controlled logistics, Biopharmaceutical distribution, Clinical trial support, Cryogenic storage and preservation, Life sciences infrastructure, Chain of compliance / regulatory compliance, Digital health logistics
Fundamentals
- Price$17.13 as of 2026-08-21 close
- Market cap$868M as of 2026-08-21
- 1-year return+101.5% 2025-08-21 close $8.50 → 2026-08-21 close $17.13
- P/E9.78 as of 2026-08-24
- Net margin-20.1% as of 2026-08-24
- Gross margin+47.1% as of 2026-08-24
- ROE-7.5% as of 2026-08-24
- Debt / equity0.38 as of 2026-08-24
- Revenue growth (YoY)-8.0% as of 2026-08-24
- Revenue CAGR (3y)-9.4% SEC XBRL
- Beta1.99 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How CYRX compares in its sector
- price-to-earnings ratiobottom 25% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CRYOPORT INC looks technically
CRYOPORT INC (CYRX) is trading 51.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 69 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It just made a new 20-day high, pushing above its recent trading range. It is trading right at its highest price of the past year (its 52-week high).
Trend
8
| Distance from the 200-day | it is trading 51.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +51.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $15.49 | $15.49 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $11.34 | $11.34 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 14.32. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 69 trading days ago — a "golden cross", a bullish long-term signal | 69 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend) | 22.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30) | 67.5 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($14.32 to $17.20) — its "stochastic" reading is 98 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 97.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $17.20 | $17.20 |
|---|---|---|
| From the 52-week high | it is trading right at its highest price of the past year (its 52-week high) | -0.4% |
| Above the 52-week low | it is 125.1% above its 52-week low (its lowest price of the past year) | +125.1% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.4% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $770.78 (set on 2005-11-22) | $770.78 |
| Given back of the 52-week move | over the past year its closes ranged ($7.72 to $17.13), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $11.01 to $11.31. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 97.8% below its all-time high | -97.8% |
| Nearest price level | it is trading 2.2% above a support level at $16.75 — a price it turned at three times since 2026-06-03, most recently on 2026-07-17. Since 2024-08-21 it has 20 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.2% |
| All-time low | its lowest closing price on record is $1.03 (set on 2016-02-09) | $1.03 |
| Above the all-time low | it is 1562.9% above its all-time low | +1,563% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 47th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7055 between its high and its low — about 4.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7055 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $14.11 and $16.58 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $14.11 – $15.35 – $16.58 |
| Typical daily range (% of price) | its price moves about 4.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.1% |
| Stretch from the 200-day average | it is trading 8.2 daily ranges above its 200-day average price (51.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.72× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.5% |
|---|---|---|
| Open gap | it gapped 2.1% above the previous close 2 sessions ago and has not traded back through the level it left behind at 15.09 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.0% |
| Gap filled | a 4.2% gap up opened on 2026-08-07 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 10 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +13.52% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 3.1 percentage points (the stock gained 5.5% while the market gained 2.3%) | +3.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 17.4 percentage points (the stock gained 20.5% while the market gained 3.1%) | +17.4% |
| vs market, 6 months | over the past 6 months this stock beat the market by 91.9 percentage points (the stock gained 103.0% while the market gained 11.1%) | +91.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 81.0 percentage points (the stock gained 101.5% while the market gained 20.5%) | +81.0% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 9.3% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 14.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +9.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 33% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $12.86 — a volume-weighted average of daily closes over 156 sessions, not a true tick-by-tick VWAP. | +33.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 10% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $15.64 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +9.5% |
Price levels it has turned at before
CYRX last closed at $17.13 on 2026-08-21. Since 2024-08-21 it has turned at 20 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $16.75 | Support | 2.2% below the last close | turned there three times · 2026-06-03 to 2026-07-17 |
| $14.71 | Support | 14.1% below the last close | turned there three times · 2026-07-08 to 2026-07-29 |
| $14.30 | Support | 16.5% below the last close | turned there twice · 2026-06-11 to 2026-08-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $14.32.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 6 trading days, since 2026-08-14.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Near the 52-week high · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · beating the market · Stretched far above its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.33 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$19.33 range $15.00 – $25.00; median $20.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CYRX
- Consensus EPS estimate-$0.1733 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Concentration risk: Dependent on CGT market growth and customer adoption; revenue declined 14.85% YoY as of mid-2026","Operational complexity: Managing global temperature-controlled supply chain requires stringent regulatory compliance and specialized infrastructure; loss from continuing operations in Q1 2026","Integration and divestiture execution: Recently divested CRYOPDP specialty courier business to DHL; reliance on new partnership to maintain service delivery in EMEA and APAC regions"]
What changed in the latest 10-Q
AI-assisted comparison of CYRX's 10-Q filed 2026-05-05 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- In newer filing: reference to 'Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 5, 2026' (vs. 2024 in older)
- In newer filing: forward-looking statement regarding 'the war with Iran' as a geopolitical risk factor
- In newer filing: 'including the anticipated expansion of the cell and gene therapy market' added to forward-looking statements
- In newer filing: updated clinical trial metrics 'As of March 31, 2026, we supported 766 clinical trials, of which 91 were in Phase 3, and 21 commercial therapies' (vs. 745/83/19 as of September 30, 2025 in older)
- In newer filing: description of solutions as 'purpose-built to support a broad range of global life sciences markets' with expanded list including 'animal health markets, reproductive medicine, academic institutions, research, and government agencies'
- Removed:
- In older filing: reference to '2024 Annual Report for the year ended December 31, 2024, as filed with the SEC on March 7, 2025' (replaced with 2025 Annual Report in newer)
- In older filing: 'the continued U.S. federal government shutdown' as a risk factor (removed in newer)
- In older filing: 'plans relating to our cost reduction and capital realignment measures and expectations about resulting annual cost savings and financial impact' from forward-looking statements (removed in newer)
- In older filing: 'our ability to retain and hire key personnel' as a risk factor related to CRYOPDP Transaction (removed in newer)
- In older filing: company description emphasizing 'an emphasis on regenerative medicine' and detailed listing of 'Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems' (simplified in newer)
- In older filing: company tagline 'Enabling the Future of Medicine™' (removed in newer)
- In older filing: reference to 'contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers' in customer description (removed in newer)
- Reworded:
- Older: 'context suggest otherwise' changed to 'context suggests otherwise' in newer (grammar correction)
- Older: 'CRYOPDP Transaction (as defined in this Quarterly Report)' changed to 'CRYOPDP divestiture' in newer (terminology shift)
- Older: 'our expectations relating to current supply chain impacts' changed to 'expectations relating to current supply chain impacts, tariffs, and other trade restrictions' in newer (added specificity)
- Older: 'projected trends in the markets in which we operate' changed to 'projected trends in the markets in which we operate, including the anticipated expansion of the cell and gene therapy market' in newer (added detail)
- Older: 'advanced temperature-controlled supply chain platform' changed to 'advanced integrated temperature-controlled supply chain solutions platform' in newer (added 'integrated')
- Older: 'Over the last several years' changed to 'Over the past several years' in newer
- Older: 'have grown to become a leader' changed to 'have established ourselves as a leading provider' in newer (different phrasing)
- Older: 'receive commercial approval from the respective regulatory agen[cies]' language in older appears cut off; newer text also appears truncated at similar point
- Notes:
- Both document excerpts appear to be truncated at the end, so comparison of final sections may be incomplete
- References to 2025 vs. 2024 annual reports reflect natural progression between quarterly filings from different periods
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 4 sells ($4M) — 3 selling insiders
- Last 180 days0 buys · 8 sells ($4M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-11. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CYRX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CYRX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 5,661,309
- Reported value $46,875,639
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CYRX had 2,499,552 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CYRX had 4.94% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.04 days to cover at the same settlement.
- Reported short interest (shares) 2,499,552
- Short interest (% of shares outstanding) 4.94%
- Prior settlement (shares) 2,520,691
- Reported change -0.84%
- Days to cover (reported) 4.04
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- World Courier (specialty life sciences logistics)
- DHL Supply Chain (after acquiring CRYOPDP specialty courier operations)
- Agility (temperature-controlled logistics)
- Lonza (cell and gene therapy CDMO and supply chain)
- FUJIFILM Diosynth (cell and gene therapy manufacturing and logistics)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Frequently asked questions
What does CRYOPORT INC (CYRX) do?
Cryoport is a leading provider of integrated, temperature-controlled supply chain solutions for the life sciences, with specialization in cell and gene therapy (CGT). The company operates through three business units—Cryoport Systems (BioLogistics, BioServices, and cryopreservation), CryoGene (long-term biostorage), and MVE Biological Solutions (cryogenic equipment manufacturing)—delivering end-to-end Chain of Compliance solutions for clinical trials and commercialized therapies.
What sector is CRYOPORT INC (CYRX) in?
CRYOPORT INC (CYRX) is classified in the Health Care sector. Its industry is Cell and gene therapy supply chain / temperature-controlled life sciences logistics. It trades on NASDAQ.
Who are CRYOPORT INC's (CYRX) competitors?
Notable peers of CRYOPORT INC (CYRX) include World Courier (specialty life sciences logistics), DHL Supply Chain (after acquiring CRYOPDP specialty courier operations), Agility (temperature-controlled logistics), Lonza (cell and gene therapy CDMO and supply chain) and FUJIFILM Diosynth (cell and gene therapy manufacturing and logistics). This peer set is informational only — not financial advice.
Is CRYOPORT INC (CYRX) overbought or oversold right now?
CRYOPORT INC (CYRX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 67, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CYRX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.